Clinical Report—Probiotics and Prebiotics in Pediatrics

Dan W. Thomas, MD, Frank R. Greer, MD, and COMMITTEE ON NUTRITION; SECTION ON GASTROENTEROLOGY, HEPATOLOGY, AND NUTRITION

KEY WORDS
probiotics, prebiotics, pediatrics, supplements, nutrition

ABBREVIATIONS
LGG—Lactobacillus rhamnosus GG
FOS—fructo-oligosaccharide
IBD—inflammatory bowel disease
RCT—randomized controlled trial
CI—confidence interval
RR—relative risk
OR—odds ratio
NEC—necrotizing enterocolitis
CUC—chronic ulcerative colitis
IBS—irritable bowel syndrome
GOS—galacto-oligosaccharide
FDA—Food and Drug Administration

INTRODUCTION

Microbes are ubiquitous and are important factors in the overall health of humans as well as the Earth. Efforts to optimize the intestinal microbial milieu have increased the interest in adding probiotics and prebiotics to nutritional products. As with antibiotics, the use and efficacy of probiotics and prebiotics should be supported by evidenced-based medicine. The purpose of this clinical report is to review the medical uses of probiotics and prebiotics and to summarize what is currently known about their health benefits as dietary supplements added to food products marketed to children, including infant formula. The guidance in this report will help pediatric health care providers to make appropriate decisions regard-
ing the usefulness and benefit of probiotics and prebiotics for their patients.

DEFINITIONS

Probiotic: An oral supplement or a food product that contains a sufficient number of viable microorganisms to alter the microflora of the host and has the potential for beneficial health effects.\(^1\)–\(^3\)

Prebiotic: A nondigestible food ingredient that benefits the host by selectively stimulating the favorable growth and/or activity of 1 or more indigenous probiotic bacteria.\(^1\)–\(^4\)

Synbiotic: A product that contains both probiotics and prebiotics. Evidence for synergy of a specific probiotic for a probiotic in the product is not essential. Synbiotics may be separate supplements or may exist in functional foods as food additives.\(^1\)–\(^3\)

Postbiotic: A metabolic byproduct generated by a probiotic microorganism that influences the host’s biological functions.\(^5\),\(^6\)

Functional food: Any modified food or food ingredient that provides a health benefit beyond that ascribed to any specific nutrient/nutrients it contains. It must remain a food, and it must demonstrate its effect in amounts normally expected to be consumed in the diet. Benefits may include functions relevant to improving health and well-being and/or reduction of risk of disease. Any food that contains probiotics or prebiotics is a functional food. An example of a functional food is live-culture yogurt that contains probiotic bacteria, prebiotics, and other dietary nutrients. Human milk may also be considered a functional food; it contains substantial amounts of oligosaccharides (prebiotics) and may contain some naturally occurring probiotic bacteria (10^10 of bifidobacteria per mL of expressed human milk, as reported in 1 study).\(^7\)

WHAT ARE PROBIOTICS?

Probiotic microorganisms are typically members of the genera *Lactobacillus*, *Bifidobacterium*, and *Streptococcus*.\(^1\)–\(^3\),\(^8\)–\(^14\) These bacteria are fermentative, obligatory, or facultative anaerobic organisms, which are typically nonmotile and of varying shapes. They typically produce lactic acid. Their inherent biological features enable them to predominate and prevail over potential pathogenic microorganisms in the human digestive tract. It is currently hypothesized that these microbes generate small molecular metabolic byproducts that exert beneficial regulatory influence on host biological functions, including short-chain fatty acids such as butyrate. These metabolic byproducts are sometimes referred to as “postbiotics” and may function biologically as immune modulators.\(^5\),\(^6\),\(^15\) The most studied probiotic bacteria to date include *Lactobacillus rhamnosus* GG (LLG), *Bifidobacterium lactis*, and *Streptococcus thermophilus*. These probiotic bacteria are biologically different from the Gram-negative, motile, non–lactic-acid–producing bacteria such as *Klebsiella*, *Pseudomonas*, *Serratia*, and *Proteus* species, which also may be prominent flora in the human digestive system. These potentially harmful bacteria may translocate across the intestinal epithelium and could result in disease in humans.\(^16\),\(^17\) Some yeasts and yeast byproducts have also been studied and have been frequently used as probiotic agents, such as the yeast *Saccharomyces boulardii*. Probiotic bacteria can be delivered and ingested separately as medicinals or supplements. They can also be mixed with, added to, or naturally exist in functional foods.

WHAT ARE PREBIOTICS?

Prebiotics are usually in the form of oligosaccharides, which may occur naturally but can also be added as dietary supplements to foods, beverages, and infant formula.\(^4\) Although indigestible by humans, their presence in the digestive system selectively enhances proliferation of certain probiotic bacteria in the colon, especially *Bifidobacteria* species. Prebiotic oligosaccharides often contain fructose chains with a terminal glucose and typically consist of 10 or fewer sugar molecules. Examples of prebiotic oligosaccharides include fructo-oligosaccharides (FOSs), inulin, galacto-oligosaccharides (GOSs), and soybean oligosaccharides. Inulin is a composite oligosaccharide that contains several FOS molecules. The complex polysaccharides that constitute dietary fiber can also be considered to be prebiotic agents.

Although dietary nucleotides do not fit the exact definition of a probiotic, they are probiotic-like agents and have immunomodulating and direct intestinal biological properties.\(^18\) Some infant formulas contain a limited amount of added free nucleotides (7–20 mg/dL).\(^18\) Human milk, on the other hand, contains a substantial but variable amount of oligosaccharides (14 g/L) as well as free nucleotides (up to 20% of nonprotein nitrogen).\(^19\) Some infant-formula manufacturers now add prebiotic oligosaccharides to their products.

Beverages and nutritional supplements marketed for older infants, children, and adults contain oligosaccharides and nucleotide additives in varying amounts.

INTESTINAL BACTERIAL COLONIZATION AND DEVELOPMENT OF THE INTESTINAL MUCOSAL DEFENSE SYSTEM

Similar to the fetus, an infant at the time of birth has a sterile gastrointestinal tract, but bacterial colonization occurs rapidly.\(^20\)–\(^22\) The newborn in-
Typically, 500 different bacteria far outnumber aerobic coliforms, or enteric bacteria, and anaerobic bacteria in the human body. The human microbiome refers to the unique entire population of microorganisms and their complete genetic elements that inhabit one’s body.

The intestinal mucosal defense system is an integral part of a sophisticated immunoregulatory network that includes the intestinal microflora. Recognition of self- and non-self-antigens begins early in life, perhaps even in utero, and is significantly influenced by events that occur within the digestive system soon after birth. The immunoresponsiveness of the digestive system is significantly affected by the young infant’s diet, state of bacterial colonization, and early exposure to potential infectious pathogens and antibiotics as well as the infant’s genotype. It is thought that the occurrence of many diseases, both intestinal and nonintestinal, can be related to dysregulation or interference with the early development of the intestinal mucosal defense system. Examples of these diseases include those thought to be atopic (asthma, eczema, and allergic rhinitis) or autoimmune (multiple sclerosis, type 1 diabetes mellitus, and chronic inflammatory bowel disease (IBD)). Certainly, the overriding determining factor in development of the immune system is one’s genetic predisposition.

The molecular basis for innate and acquired immunity is thought to reside in the recognition and response of mature T lymphocytes to trigger molecules, such as those derived from dietary and bacterial-breakdown products within the intestinal tract. Triggers molecules also include dietary nucleotides and oligosaccharides. Toll-like receptors located in the surface membrane of T lymphocytes facilitate recognition of these trigger molecules, which eventually leads to specialized T-lymphocyte recognition and response to subsequent exposure to the same or very similar molecules. Thus, T-lymphocyte recognition of specific oligosaccharides bound to intestinal pathogens plays an important role in preventing gastrointestinal illness.

Given these important influences on intestinal microflora colonization and immune function, the infant’s early diet and intestinal microbial environment are thought to serve as pivotal factors in overall health. Probiotic bacteria, postbiotic bacterial byproducts, and dietary prebiotics are believed to exert positive effects on the development of the mucosal immune system. It is also believed that exposure to “nonbeneficial” microorganisms and antimicrobial agents in the newborn period may result in immune dysregulation in susceptible individuals and may lead to some chronic disease states. There is evidence that human milk contains mononuclear cells that traffic intestinally derived bacterial components from the mother to her infant. The ingested human milk containing the bacterial components derived from the mother are thought to influence her young infant’s developing immune system. This process is termed “bacterial imprinting,” and its overall biological effect requires further study.

**USE OF PROBIOTICS IN PREVENTION AND TREATMENT OF CLINICAL DISEASES**

Reviews on the clinical applications of probiotics and prebiotics can be found in the references. Results of evidence-based analyses of the clinical effectiveness of probiotics and prebiotics are discussed below. It must be stressed that the current lack of evidence of efficacy does not mean that future clinical research will not establish significant health benefits for probiotics and prebiotics.
Acute Infectious Diarrhea

**Prevention of Acute Infectious Diarrhea**

Results of published randomized controlled trials (RCTs) have indicated that there is modest benefit of giving probiotics in preventing acute gastrointestinal tract infections in healthy infants and children.32–35 Most of the studies were conducted in child care centers. The strains of probiotics used included LGG, *S thermophilus*, *Lactobacillus casei*, *B lactis*, or *Lactobacillus reuteri* mixed with milk or infant formula or given as an oral supplement. Rotavirus was the most common cause of acute diarrhea in the RCTs.

In a double-blind, placebo-controlled trial by Weizman et al.,26 201 infants (4–10 months of age) received either a probiotic-supplemented formula containing either *B lactis* or *L reuteri* or a control formula without an added probiotic over a 12-week study period. The study was conducted at 14 different child care centers over a 2-year period. Infants fed a probiotic-supplemented formula had fewer and shorter episodes of diarrhea than did infants in the control group. Infants in the control group had a mean of 0.59 days of diarrhea (95% confidence interval [CI]: 0.34–0.84 days) per infant compared with 0.37 days (95% CI: 0.08–0.66 days) in the *B lactis* and 0.15 days (95% CI: 0.12–0.18 days) in the *L reuteri* probiotic-supplemented study groups (*P < .001*). During the 12-week study period, the infants in the control group were found to have a mean of 0.31 episodes of diarrhea (95% CI: 0.22–0.44 episodes) compared with 0.12 episodes (95% CI: 0.05–0.21 episodes) and 0.02 episodes (95% CI: 0.01–0.05 episodes) in the *B lactis*– and *L reuteri*–supplemented study groups, respectively (*P < .001*). There was no significant effect found on the incidence of acute respiratory illnesses. In another study conducted in child care centers in France,37 928 healthy children were randomly assigned to be fed either standard yogurt or yogurt supplemented with *L casei* for 4 months. The children who were fed the probiotic-supplemented yogurt had fewer episodes of diarrhea during the study period than did those who were fed standard yogurt (15.9% vs 22%; *P = .03*).

The results of a meta-analysis of probiotic prevention of acute rotavirus gastroenteritis in child care centers indicated that approximately 7 children would need to have been given LGG to prevent 1 child from developing nosocomial rotavirus gastroenteritis in a child care center setting.38 To date, the available data do not support routine use of probiotics to prevent nosocomial rotavirus diarrhea in child care centers. However, there may be special circumstances in which probiotic use in children in long-term health care facilities or in child care centers is beneficial. The use of the newly available pentavalent rotavirus vaccine in the United States39 will likely be a more formidable preventative agent than the use of probiotics in reducing the incidence of the most common form of acute infantile infectious diarrhea.

**Treatment of Acute Infectious Diarrhea**

Well-conducted RCTs in healthy children in developed countries have provided good data on the therapeutic benefit of probiotics in children with acute infectious diarrhea. In a randomized, double-blind, placebo-controlled trial by Szymanski et al.,40 administration of LGG significantly shortened the duration of acute rotavirus diarrhea by a mean of 40 hours, but duration of diarrhea of any other etiology was not affected. Probiotic administration also shortened the time necessary for intravenous rehydration by a mean of 18 hours. Results of several other meta-analyses41–45 and a Cochrane review44 have been published on the benefit of probiotics for treatment of acute infectious diarrhea in children. These reports indicate that probiotics reduce the number of diarrheal stools and the duration of the diarrhea by approximately 1 day. The benefit is strain-dependent. LGG is the most effective probiotic reported to date and is dose-dependent for doses greater than 1010 colony-forming units. Probiotics also seem to be more effective when given early in the course of diarrhea and are most helpful for otherwise healthy infants and young children with watery diarrhea secondary to viral gastroenteritis but not invasive bacterial infections. Thus, there is evidence to support the use of probiotics, specifically LGG, early in the course of acute infectious diarrhea to reduce the duration by 1 day.

**Antibiotic-Associated Diarrhea**

**Prevention of Antibiotic-Associated Diarrhea**

Meta-analysis of published results of RCTs of probiotic use in the prevention of antibiotic-associated diarrhea in children indicates a beneficial effect.45–48 Treatment with a probiotic was started when antibiotic therapy was initiated for treatment of an acute respiratory infection (otitis media) in most of these studies. Treatment with probiotics compared with placebo reduced the risk of developing antibiotic-associated diarrhea from 28.5% to 11.9% (relative risk [RR]: 0.44 [95% CI: 0.25–0.77]; *P = .006*).45 LGG, *B lactis*, *S thermophilus*, and *S boulardii* have been the most common agents used in RCTs. Approximately 1 in 7 cases of antibiotic-associated diarrhea was prevented by the use of a probiotic.45 Children in these studies received either a probiotic-supplemented formula or a separate
probiotic as preventive treatment. According to 1 reported meta-analysis, probiotic treatment significantly reduced odds of antibiotic-associated diarrhea as compared with placebo (odds ratio [OR]: 0.39 [95% CI: 0.25–0.62]; \( P < .001 \)) for both the yeast by-product \( S \) \( boulardii \) and LGG. There was no significant difference between the 2 treatments; the overall combined OR was 0.37 (95% CI: 0.26–0.53; \( P < .001 \)) in favor of active probiotic treatment over placebo. Thus, probiotics can be used to reduce the incidence of antibiotic-associated diarrhea.

**Treatment of Antibiotic-Associated Diarrhea**

There have been no published RCTs of children that have investigated the effect of probiotics for treatment of antibiotic-associated diarrhea. Thus, their use cannot be recommended. The clinician who is caring for a child with antibiotic-induced diarrhea must weigh the benefits of considering therapy with a probiotic or discontinuing or modifying the antibiotic treatment when possible. No RCTs have been published concerning treatment with probiotics of children with \( C l o s t r i d i u m \) \( d i f f i c i l e \) antibiotic-associated diarrhea.

**Atopic Diseases**

**Prevention of Atopic Disease**

As previously mentioned, the sequence of bacterial intestinal colonization of neonates and young infants is probably important in the development of the immune response. Recognition by the immune system of self and nonself, as well as the type of inflammatory responses generated later in life, are likely affected by the infant’s diet and acquisition of the commensal intestinal bacterial population superimposed on genetic predisposition. During pregnancy, the cytokine inflammatory-response profile of the fetus is diverted away from cell-mediated immunity (T-helper 1 [Th1] type) toward humoral immunity (Th2 type). Hence, the Th2 type typically is the general immune response in early infancy. The risk of allergic disease could well be the result of a lack or delay in the eventual shift of the predominant Th2 type of response to more of a balance between Th1- and Th2-type responses. Administration of probiotic bacteria during a time period in which a natural population of lactic-acid–producing indigenous intestinal bacteria is developing could theoretically influence immune development toward more balance of Th1 and Th2 inflammatory responses. The intestinal bacterial flora of atopic children has been demonstrated to differ from that of nonatopic children. Specifically, atopic children have more \( C l o s t r i d i u m \) organisms and fewer \( B i f i d o b a c t e r i u m \) organisms than do nonatopic study subjects, which has served as the rationale for the administration of probiotics to infants at risk of atopic diseases, particularly for those who are formula fed.

In a double-blinded RCT, LGG or a placebo was given initially to 159 women during the final 4 weeks of pregnancy. If the infant was at high risk of atopic disease (atopic eczema, allergic rhinitis, or asthma), the treatment was continued for 6 months after birth in both the lactating woman and her infant. A total of 132 mother-infant pairs were randomly assigned to receive either placebo or LGG and treated for 6 months while breastfeeding. The primary study end point was chronic recurrent atopic eczema in the infant. Atopic eczema was diagnosed in 46 of 132 (35%) of these study children by 2 years of age. The frequency of atopic eczema in the LGG-treated group was 15 of 64 (23%) versus 31 of 68 (46%) in the placebo group (RR: 0.51 [95% CI: 0.32–0.84]; \( P < .01 \)). The number of mother-infant pairs required to be treated with LGG to prevent 1 case of chronic recurrent atopic eczema was 4.5. By 4 years of age, eczema occurred in 26% of the infants in the group treated with LGG, compared with 46% in the placebo group (RR: 0.57 [95% CI: 0.33–0.97]; \( P < .01 \)). However, only 67% of the original study group was analyzed at the 4-year follow-up. These results support a preventive effect for giving a probiotic to mothers late in pregnancy and to both mothers and infants during the first 6 months of lactation for the prevention of atopic eczema in infants who are at risk of atopic disease. However, these results have not been confirmed in subsequent clinical trials, as summarized in a recent review by Kopp and Saiffeld. Conversely, Taylor et al found that probiotic supplementation did not reduce the risk of atopic dermatitis in children at high risk with the report of some increased risk of subsequent allergen sensitization. As concluded in a review by Prescott and Björkstén and in a 2007 Cochrane review, despite the encouraging results of some studies, there is insufficient evidence to warrant the routine supplementation of probiotics to either pregnant women or infants to prevent allergic diseases in childhood. Explanations for varied study results include host factors such as genetic susceptibility, environmental factors such as geographic region and diet, and study variables including probiotic strains and doses used.

**Treatment of Atopic Disease**

In an RCT, 53 Australian infants with moderate-to-severe atopic dermatitis were given either \( L a c t o b a c i l l u s \) \( f e r m e n t u m \) or placebo for 8 weeks. At final assessment at 16 weeks, significantly more children who received the probiotic had improved extent and severity of atopic dermatitis as measured by the Severity of Scoring of...
Atopic Dermatitis (SCORAD) index over time compared with those who received placebo \((P = .01)\). These results are encouraging, but as summarized in a 2008 Cochrane review, probiotics have not yet been proven to be effective in the treatment of eczema.

**Prevention of Necrotizing Enterocolitis in Low Birth Weight Neonates**

A newborn’s gut is sterile at birth, with bacterial colonization beginning shortly after birth. Preterm infants frequently have delayed and aberrant acquisition of the “normal” digestive microflora, possibly because of restricted enteral feedings and frequent use of antibiotic therapy. Delayed enteral feeding, frequent use of antibiotic therapy, and altered acquisition of normal digestive microflora are believed to be primary contributing factors for the increased risk of necrotizing enterocolitis (NEC) in preterm infants and is the rationale for probiotic supplements.

In a 2008 Cochrane review based on 9 RCTs, enteral probiotic supplementation significantly reduced both the incidence of NEC (stage II or more) \((RR: 0.32 \pm 0.60)\) and mortality \((RR: 0.43 \pm 0.75)\). Nosocomial sepsis was not reduced significantly \((RR: 0.93 \pm 1.19)\). A total of 1425 infants who were born at less than 37 weeks’ gestational age and/or less than 2500 g birth weight were included in this meta-analysis. No systemic infections or serious adverse events that were directly attributed to the administered probiotic organism were reported for these RCTs. The authors concluded that the results of their analysis supported a change in clinical practice to supplement preterm infants with less than 1000 g at birth with a probiotic. Data regarding the outcome of preterm extremely low birth weight infants who weighed less than 1000 g at birth could not be used by the authors to reliably estimate the efficacy and safety of probiotic supplementation to this high-risk group. A large RCT was recommended to investigate the potential benefit and safety of probiotic supplementation to extremely low birth weight infants.

However, because the of large heterogeneity of the studies included in the Cochrane review, caution is urged in interpreting the results, which are somewhat problematic. The studies all used different probiotics, including *Lactobacillus acidophilus*, *Bifidobacterium breve*, *Saccharomyces* species, and mixtures of *Bacteroides bifidus*, *S. thermodphilus*, *Lactobacillus acidophilus*, and *Bifidobacterium infantis*. Doses of individual probiotics varied and were administered with human milk feedings, formula feedings, or both human milk and formula feedings in some studies. Not all of the studies had the same end points, including the primary outcome of NEC. A second and larger study by Lin et al., the results of which were published after the Cochrane review, repeated the 2005 study by using a different mixture of probiotics: *L. acidophilus* and *B. bifidus*. The overall incidence of NEC and death was less in the second study compared with that in the first in the controls, and the second study revealed that probiotics did not reduce the incidence of sepsis compared with that in the first, and the intervention group actually had a higher incidence of sepsis. The number needed to treat to prevent 1 case of NEC was 27 in the first study by Lin et al. and 21 in the second study. Another point that makes the data problematic is that the combinations of probiotics used in the Lin et al. studies, which are the most convincing for NEC prevention, are not available in the United States. Not all probiotics have been studied; therefore, all probiotics cannot be generally recommended.

**Treatment of Helicobacter pylori Infection**

There is a modest and encouraging benefit in published RCT results for probiotics used as adjunctive therapy for *H. pylori* gastritis in adults. One RCT in children has been published, and the results demonstrated that the probiotics-supplemented treatment group had better *H. pylori* eradication than did the placebo group (84.6% vs 57.5%; RR: 1.47 [95% CI: 1.1–2.0]). The adverse effects of diarrhea, nausea, and vomiting in both the placebo and probiotic treatment group did not differ significantly. Thus, probiotics may be of some benefit in the eradication of *H. pylori* in children, but more studies are required.

**Chronic IBD**

The term IBD is inclusive of patients with either chronic ulcerative colitis (CUC) or Crohn disease. It is estimated that approximately 40% to 70% of children and adult patients suffering with IBD routinely use alternative medicines, including probiotics, as adjunctive or replacement therapy for prescribed medications. In theory, probiotics may be beneficial in the treatment of IBD. It has been proposed that in individuals with genetic susceptibility to IBD, chronic inflammation occurs in response to commensal digestive microflora because of various inherited defects of innate inflammatory-response pathways. One such identified inherited defect found in patients with Crohn disease is a mutation of the *CARD15* gene on chromosome 16, which results in abnormal chronic inflammation in response to bacteria such as *Escherichia coli* in the digestive tract. Hence, modulating the commensal intestinal bacterial environment with probiotic supplements...
may reduce the inflammatory response in patients with IBD.

**Treatment of Chronic Ulcerative Colitis**

Data from RCTs of probiotics for the treatment of adults with CUC are encouraging. The administration of probiotics to adults with mild-to-moderate CUC disease activity has comparable efficacy when compared with treatment with anti-inflammatory drugs used to treat CUC, such as mesalamine, as reported in a recently published Cochrane review. The same is true in adult patients with ileo-anal pouchitis after colectomy surgery for CUC. Most of these studies use the probiotic mixture VSL#3 (Sigma-Tau Pharmaceuticals, Gaithersburg, MD), which is a combination of *S. thermophilus*, *Bifidobacterium* species, and *Lactobacillus* species. The probiotic *E. coli* Nissle 1917 (Ardeypharma GmbH, Herdecke, Germany) has also been used successfully to treat mild-to-moderate pouchitis or CUC in adults. One RCT in which 29 children with newly diagnosed CUC were randomly assigned to receive either VSL#3 or a placebo for 1 year had promising results. All study patients were also given standard corticosteroid induction therapy combined with mesalamine maintenance therapy. Remission occurred in 13 patients (92.8%) in the VSL#3 group and 4 patients (36.4%) in the placebo group (*P* < .001). Relapse occurred in 3 of 13 (23%) patients in the VSL#3 group versus 11 of 15 (73.3%) in the placebo group within the 1-year study period (RR: 0.32 [95% CI: 0.25–0.773]; *P* = .014). Although these results are promising, more studies are needed in larger numbers of children to substantiate the benefit of probiotics in managing children with mild-to-moderate CUC. Thus, probiotics for CUC cannot be generally recommended at this time without further confirmatory research.

**Treatment of Crohn Disease**

One RCT in which LGG was used in pediatric patients with Crohn disease resulted in no significant benefit. Treating adults with Crohn disease with the probiotics *S. boulardii*, LGG, and *E. coli* Nissle 1917 has not yielded promising results thus far. A recent Cochrane review indicated that there is, as yet, no proven benefit for maintaining remission by administering probiotics to adults with Crohn disease. Because of the lack of efficacy, treatment of Crohn disease with probiotics cannot be recommended for children.

**Irritable Bowel Syndrome and Constipation: Treatment**

There has been a single published RCT of the treatment of irritable bowel syndrome (IBS) in children. LGG reduced abdominal distension and discomfort in a group of 50 pediatric patients over a 6-week study period. Response to therapy was recorded and collected on a weekly basis by using the Digestive Symptom Rating Scale. Various probiotics were shown to be helpful in several other RCTs of treatment of IBS in adults. One published RCT addressed the use of probiotics (LGG) or a placebo as adjunct therapy to a stool softener (lactulose) to treat functional constipation in 84 children. LGG was not an effective adjunct to lactulose in treating constipation in children. Thus, probiotics may be of benefit in children with IBS on the basis of a single RCT, but a recommendation for their use cannot be made without further confirmatory studies. Probiotics cannot be recommended at this time for treatment of constipation.

**Extraintestinal Infections**

**Prevention of Extraintestinal Infections**

In a 2001 RCT in 17 Finnish child care centers, 571 healthy children 1 to 6 years of age were studied for 7 months in winter. Children were randomly assigned to receive milk 3 times per day with or without LGG. When the data were adjusted for age, children who were fed milk with LGG, compared with controls, did not have significantly fewer days with respiratory symptoms.
or fewer days of child care absences because of illness. There were also no significant differences in the numbers of children with a doctor’s diagnosis of infection or number of prescriptions for antibiotics when adjusted for age, although the trends favored the children who were fed milk with LGG. Thus, probiotics for the prevention of extraintestinal infections in children cannot be recommended at this time.

**Treatment of Extraintestinal Infections**

No RCTs in children have demonstrated definite beneficial effects of administering probiotics to treat extraintestinal infections. The beneficial effects that have been reported in uncontrolled trials in adults with 1 or more types of extraintestinal infection have typically used LGG as a supplement or probiotics added to dairy products.101–103 Thus, probiotics are not recommended for children for treatment of extraintestinal infections.

**Cancer: Prevention and Treatment**

Results of published studies have demonstrated the positive benefits of functional foods, such as yogurt, and the administration of probiotics to prevent carcinogenic processes in animal models.104 As yet, no published RCTs warrant recommendation of routine administration of probiotics to either treat or prevent cancer in adults or children.

**USE OF PREBIOTICS IN PREVENTION AND TREATMENT OF CLINICAL DISEASES**

Few RCTs have been conducted to evaluate the use of prebiotics in preventing or treating specific childhood diseases.8

**Prevention and Treatment of Allergy**

A 2007 Cochrane review105 concluded that there was inconclusive evidence for giving prebiotics to prevent allergic disorders in infants. However, in 2008, Arslanoglu et al106 reported on a 2-year follow-up of an RCT in 132 infants at risk of atopy because of parental atopy. Infants were fed a partially hydrolyzed formula with either an added mixture of FOS and GOS or maltodextrin placebo in the first 6 months of life. Those given the prebiotic mixture of FOS and GOS had a reduced incidence of atopic disease. Cumulative incidences of atopic eczema, recurrent wheezing, and allergic urticaria were higher in the maltodextrin placebo group (27.9%, 20.6%, and 10.3%, respectively) than in the intervention group (13.6%, 7.6%, and 1.5%) (P = .05). In a 2009 review, van der Aa et al107 analyzed relevant publications to date and concluded that there is presently not enough evidence to support the use of probiotics, prebiotics, or synbiotics for the prevention or treatment of allergic dermatitis in children. Confirmatory studies of the benefits of prebiotics, especially for children fed formula that is not partially hydrolyzed or infants fed partially hydrolyzed formula, which are already being promoted to reduce the incidence of atopic disease, are needed before any recommendations can be made for the use of probiotics in infants and toddlers to prevent infection or atopic disease.

**Other Disorders**

It has been shown that the addition of dietary fiber has ameliorated diarrheal stools when added to infant formula.108 Prebiotics, such as oligosaccharides, inulin, and dietary fiber supplements that are contained in bran, psyllium, and barley fiber, are beneficial in maintaining clinical remission in adult patients with CUC,109 but no RCT results support their use. There have been controlled animal research studies that have shown that prebiotics may prevent or lessen carcinogenic processes,104 but there have been no RCTs in humans.

**COMBINED PREBIOTICS AND PROBIOTICS TO PREVENT ALLERGY**

Clinical benefit in preventing allergic diseases by co-therapy with probiotics and prebiotics in pregnant women and their infants was demonstrated in an RCT in Finland.110 A total of 1223 pregnant women who had been identified to deliver infants who would be at high risk of atopic disease because of parental atopic disease history were randomly assigned to be given a mixture of 4 probiotic strains plus GOS or placebo daily for 2 to 4 weeks before delivery. After delivery, their infants then either received the same probiotic mixture plus GOS or the same placebo as the mother. Probiotic/prebiotic treatment showed no effect on the cumulative occurrence of allergic diseases but tended to reduce immunoglobulin E–associated (atopic) diseases (OR: 0.71 [95% CI: 0.50–1.00]; P = .052). Probiotic and prebiotic treatment reduced the occurrence of eczema (OR: 0.74 [95% CI: 0.55–0.98]; P = .035) and atopic eczema (OR: 0.66 [95% CI: 0.46–0.95]; P = .025). Confirmatory studies are necessary.

**PREBIOTICS AND PROBIOTICS IN INFANT FORMULA**

**Prebiotics**

As mentioned earlier in this review, human milk contains a number of substances that are prebiotic, the most plentiful of which are oligosaccharides.10,30 Oligosaccharide prebiotics are also added to many commercially available dietary food supplements. Regarding their addition to infant formula, the European Commission’s Scientific Committee on Food concluded in 2003111 that they had no major concerns regarding the addition of oligosaccharides to infant formulas, including follow-up infant formulas (formulas modified especially for 6- to 12-month-old infants), up to a total
Two infant formulas currently contain probiotics. One contains B lactis, and the other contains LGG. These probiotics are only added to powdered formulas at present. The rationale for adding probiotic organisms to infant formula was discussed in the introduction of this clinical report. The overall health-benefit efficacy of adding probiotics to infant formula remains to be demonstrated in large RCTs.

SAFETY OF PROBIOTICS AND PREBIOTICS IN INFANTS AND CHILDREN

Concerns exist about the overall safety of administering probiotic products to high-risk patient groups, including adults, children, and term and preterm infants. Cases of serious infection have occurred and been reported in the literature. Patients at risk would be those who are immunocompromised, including ill preterm neonates, and/or children who have intravenous catheters or other indwelling medical devices. In most cases, the offending organism that caused the sepsis seems to have stemmed from bacteria from the individual’s own endogenous flora. Sepsis has also been reported in adults, children, and infants who received probiotic supplements. Land et al recently reported LGG probiotic sepsis occurring in immunocompromised infants and children. A medically fragile infant 6 weeks of age became septic with a strain of LGG that was being provided as a supplement. Molecular DNA-fingerprinting confirmed that the LGG probiotic supplement was the bacterial isolate from the infant. Neonatal sepsis and meningitis that were apparently associated with the administration of a probiotic supplement were also reported.

A recent report focused on probiotic tolerance and safety in healthy term infants who were randomly assigned to be given a high-dose probiotic formula, a low-dose probiotic formula, or control formula for 18 months. There were no apparent reported adverse events. All infants demonstrated normal growth. Reports of colic were significantly fewer in the 2 probiotic-formula-fed groups, and the frequency of health care visits and antibiotic use was less (P < .001) compared with those in the control formula group. In a separate study, Petschow et al reported that healthy term infants given varying amounts of LGG in infant formula for 2 weeks resulted in good overall feeding tolerance with successful intestinal tract colonization, without adverse events.

The apparent safety to date of adding probiotics to infant formula has been evaluated in the previously discussed RCTs reported by Boehm et al, Moro et al, Schmelzle et al, and Bettler and Euler.

SUMMARY ON SAFETY

The Committee on Nutrition of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition previously concluded that more studies are required to establish the safety and efficacy of probiotic and prebiotic products in children. To date, these products seem to be safe for healthy infants and children. The committee also stated that it would be optimal to have a centralized mechanism of oversight to ensure probiotic microorganism safety, identity, and genetic stability. Centralized oversight and probiotic product monitoring was also recommended in a report from the Food and Agriculture Organization of the United Nations World Health Organization. This organization supports the addition of prebiotic products to infant formulas designed as follow-up formulas meant for infants aged 5 months and older. It was reasoned that these infants are more likely to have a more mature immune response and established intestinal
colonization. In terms of oversight and product safety in the United States, products marketed as dietary supplements, such as probiotics, do not require premarket review and approval by the US Food and Drug Administration (FDA). However, probiotics or prebiotics that are marketed specifically for the treatment or prevention of a disease are classified as biological products and do require FDA review and approval. Infant formulas must be made with compliance with what are considered good manufacturing practices under the Infant Formula Act of 1980 and are under the regulatory auspices of the FDA because these products are often used as the sole source of nutrition by infants during a critical period of growth and development. Additional statutory and regulatory requirements address appropriate infant formula manufacture, composition, and nutrient content. All ingredients used in infant formula must be safe and lawful—that is, food ingredients that are, to date, generally regarded as safe (GRAS) for use in infant formula and those that are used in accordance with the food-additive regulations of the FDA. Prebiotics and probiotics now being added to commercial infant formulas are classified as GRAS. Information on FDA regulations for infant formula and food ingredients and packaging may be found at www.fda.gov/Food/FoodSafety/Product-SpecificInformation/InfantFormula/default.htm and www.fda.gov/Food/FoodIngredientsPackaging/default.htm.

DEVELOPMENT OF THIS REPORT

The AAP Committee on Nutrition and Section on Gastroenterology, Hepatology, and Nutrition used review of the literature, including Cochrane reviews, and reports from other groups.12,111,128 Comments also were solicited from committees, sections, and councils of the AAP, 9 entities responded.

Additional comments were sought from the Centers for Disease Control and Prevention, the National Institutes of Health, the US Department of Agriculture, and the FDA because these governmental agencies have official liaisons to the Committee on Nutrition and were present during the development of the statement. For recommendations for which high levels of evidence are absent, the expert opinions and suggestions of the members of the Committee on Nutrition and other groups and authorities consulted were taken into consideration in developing this clinical report.

SUMMARY

1. Human milk, a natural prebiotic, is preferred for infants through 6 months of age.130 The oligosaccharide content of human milk is substantial and is part of the prebiotic components of the human milk. Breastfed infants typically have a preponderance of naturally occurring probiotic bacteria in their digestive systems. There may be some naturally occurring probiotic bacteria contained in human milk.

2. There is some evidence in otherwise healthy infants and young children to support the use of probiotics early in the course of diarrhea from acute viral gastroenteritis and that use of probiotics reduces its duration by 1 day. However, the available evidence does not support the routine use of probiotics to prevent infectious diarrhea unless there are special circumstances. There is some evidence to support the use of probiotics to prevent antibiotic-associated diarrhea but no evidence that it is beneficial for treatment.

3. Although the results of some studies support the prophylactic use of probiotics during pregnancy and lactation and during the first 6 months of life in infants who are at risk of atopic disorders, further confirmatory evidence is necessary before a recommendation for routine use can be made.

4. There is some evidence to support the use of probiotics to prevent NEC in preterm infants with a birth weight of 1000 g or higher. However, the amount and specificity of which probiotic or mixture of probiotics to use is problematic, given the many unanswered questions from a review of the available literature. Furthermore, many of the probiotics used and cited in the literature for treatment in preterm infants are not readily available.

5. At the present time, the sustained or long-term benefit of using probiotics for treating disorders such as Crohn disease, IBS, constipation, and extraintestinal infections requires further RCTs and cannot be recommended in children. There may benefit for treating _H pylori_ infections, OUC, and infantile colic with probiotics in childhood, but further studies are necessary.

6. Long-term health benefits of probiotics in the prevention of cancer, allergy, or other diseases or providing sustained beneficial results on the developing immune system beyond early infancy remain to be proven.

7. Addition of probiotics to powdered infant formulas has not been demonstrated to be harmful to healthy term infants. On the other hand, evidence of clinical efficacy for their addition is insufficient to recommend the routine use of these formulas. No RCTs have directly compared the health benefits of feeding human milk versus infant formula supplemented with probiotics.
8. Probiotics should not be given to children who are seriously or chronically ill until the safety of administration has been established.

9. Prebiotics may prove to be beneficial in reducing common infections and atopy in otherwise healthy children. However, confirmatory studies, especially in children fed formula that is not partially hydrolyzed, are needed before any recommendations can be made.

10. Addition of oligosaccharides as prebiotics to infant formula is not unreasonable but lacks evidence demonstrating clinical efficacy at this time. Cost/benefit studies are also necessary to support their addition to infant formulas.

11. Important questions remain in establishing the clinical applications for probiotics, including the optimal duration of probiotic administration as well as preferred microbial dose and species. The long-term impact on the gut microflora in children is unknown. It also remains to be established whether there is significant biological benefit in the administration of probiotics during pregnancy and lactation, with direct comparison to potential biological benefit derived from probiotic-containing infant formulas. Similar questions exist for the use of prebiotics.

Appendix 1 contains examples of currently available probiotic products and the probiotic content of various functional foods in the United States. This list demonstrates the wide variation in probiotic content in these products. Information about other probiotics can also be found on a Web site maintained by industry (www.usprobiotics.org).

REFERENCES


123. Kalima P, Masterton RG, Roddie PH,


APPENDIX 1 Selected Dietary Supplements

<table>
<thead>
<tr>
<th>Product</th>
<th>Active Ingredient</th>
<th>CFU Count per Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>VSL#3</td>
<td><em>S</em> thermophilus, <em>Bifidobacterium</em> species, <em>Lactobacillus</em> species</td>
<td>450 billion, combined</td>
</tr>
<tr>
<td>Culturelle</td>
<td>LGG</td>
<td>10 billion</td>
</tr>
<tr>
<td>Florastor</td>
<td><em>S</em> boulardii</td>
<td>5 billion</td>
</tr>
<tr>
<td>GNC</td>
<td><em>L</em> acidophilus</td>
<td>1.6 billion</td>
</tr>
<tr>
<td>CVS brand</td>
<td><em>L</em> acidophilus, <em>Bifidobacterium</em> longum</td>
<td>1 billion</td>
</tr>
<tr>
<td>Nature Made</td>
<td><em>L</em> acidophilus</td>
<td>500 million</td>
</tr>
<tr>
<td>Selected functional foods</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dannon Activia yogurt</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stonyfield Farm yogurt, refrigerated (not frozen)</td>
<td>*Lactobacillus bulgaricus, S thermophilus, L acidophilus, Lactobacillus casei, L reuteri, Bifidus species</td>
<td>100 000–1 million/g</td>
</tr>
<tr>
<td>Sweet acidophilus milk (Purity Dairy), refrigerated</td>
<td><em>L</em> acidophilus</td>
<td>10 million/g, combined (throughout shelf-life)</td>
</tr>
<tr>
<td>Nestle Good Start natural cultures</td>
<td><em>B</em> lactis</td>
<td>10⁷/100 kcal</td>
</tr>
<tr>
<td>Mead Johnson Nutramigen with Enflora LGG</td>
<td>LGG</td>
<td>10⁷/100 kcal</td>
</tr>
</tbody>
</table>

CFU indicates colony-forming unit.
### Probiotics and Prebiotics in Pediatrics

Dan W. Thomas, Frank R. Greer and Committee on Nutrition; Section on Gastroenterology, Hepatology, and Nutrition

*Pediatrics* 2010;126;1217

DOI: 10.1542/peds.2010-2548 originally published online November 29, 2010;

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://pediatrics.aappublications.org/content/126/6/1217">http://pediatrics.aappublications.org/content/126/6/1217</a></td>
</tr>
<tr>
<td>References</td>
<td>This article cites 113 articles, 32 of which you can access for free at:</td>
</tr>
<tr>
<td></td>
<td><a href="http://pediatrics.aappublications.org/content/126/6/1217#BIBL">http://pediatrics.aappublications.org/content/126/6/1217#BIBL</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s):</td>
</tr>
<tr>
<td></td>
<td><strong>Current Policy</strong> <a href="http://www.aappublications.org/cgi/collection/current_policy">http://www.aappublications.org/cgi/collection/current_policy</a></td>
</tr>
<tr>
<td></td>
<td><strong>Committee on Nutrition</strong> <a href="http://www.aappublications.org/cgi/collection/committee_on_nutrition">http://www.aappublications.org/cgi/collection/committee_on_nutrition</a></td>
</tr>
<tr>
<td></td>
<td><strong>Section on Gastroenterology, Hepatology and Nutrition</strong> <a href="http://www.aappublications.org/cgi/collection/section_on_gastroenterology_hepatology_and_nutrition">http://www.aappublications.org/cgi/collection/section_on_gastroenterology_hepatology_and_nutrition</a></td>
</tr>
<tr>
<td></td>
<td><strong>Gastroenterology</strong> <a href="http://www.aappublications.org/cgi/collection/gastroenterology_sub">http://www.aappublications.org/cgi/collection/gastroenterology_sub</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:</td>
</tr>
<tr>
<td></td>
<td><a href="http://www.aappublications.org/site/misc/Permissions.xhtml">http://www.aappublications.org/site/misc/Permissions.xhtml</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online:</td>
</tr>
<tr>
<td></td>
<td><a href="http://www.aappublications.org/site/misc/reprints.xhtml">http://www.aappublications.org/site/misc/reprints.xhtml</a></td>
</tr>
</tbody>
</table>
Probiotics and Prebiotics in Pediatrics
Dan W. Thomas, Frank R. Greer and Committee on Nutrition; Section on Gastroenterology, Hepatology, and Nutrition
Pediatrics 2010;126;1217
DOI: 10.1542/peds.2010-2548 originally published online November 29, 2010;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/126/6/1217